ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SGMO Sangamo Therapeutics Inc

0.5558
0.00 (0.00%)
Pre Market
Last Updated: 13:38:51
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sangamo Therapeutics Inc NASDAQ:SGMO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.5558 0.5377 0.565 72 13:38:51

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

30/09/2019 1:30pm

Business Wire


Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that members of the management team will present at the following investor and industry conferences in October:

Cell & Gene Meeting on the Mesa 2019 Corporate presentation Wednesday, Oct 2nd at 3:15 p.m. Pacific Time Location: Carlsbad, CA

Panel: What does the future hold for gene editing? Friday, Oct 4th at 9:45 a.m. Pacific Time Location: Carlsbad, CA

Cantor Global Healthcare Conference 2019 Friday, Oct 4th at 11:15 a.m. Eastern Time Location: New York, NY

Chardan 3rd Annual Genetic Medicines Conference Monday, Oct 7th at 8:30 a.m. Eastern Time Location: New York, NY

Jefferies Gene Therapy/Editing Summit Tuesday, Oct 8th at 11:15 a.m. Eastern Time Location: New York, NY

Presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.

Investor Relations – Global McDavid Stilwell 510-970-6000, x219 mstilwell@sangamo.com

Media Inquiries – Global Aron Feingold 510-970-6000, x421 afeingold@sangamo.com

1 Year Sangamo Therapeutics Chart

1 Year Sangamo Therapeutics Chart

1 Month Sangamo Therapeutics Chart

1 Month Sangamo Therapeutics Chart

Your Recent History

Delayed Upgrade Clock